Evogene Ltd. (EVGN)

Evogene Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	12.96	15.3
Cash & Short-Term Investments	12.96	15.3
Cash Growth	-15.33%	-
Accounts Receivable	0.32	1.09
Other Receivables	1.57	2.06
Total Trade Receivables	1.88	3.16
Inventory	0.21	1.82
Other Current Assets	0.58	1.31
Total Current Assets	15.63	21.59
Net Property, Plant & Equipment	2.64	4.25
Other Intangible Assets	-	12.2
Long-Term Investments	0.04	0.08
Other Long-Term Assets	1.74	1.75
Total Assets	20.05	39.86
Accounts Payable	0.64	1.23
Accrued Expenses	0.86	1.87
Short-Term Debt	-	10.37
Current Portion of Leases	0.72	0.59
Unearned Revenue	0.02	0.36
Other Current Liabilities	1.21	4.28
Total Current Liabilities	3.44	18.7
Long-Term Leases	1.48	1.91
Other Long-Term Liabilities	3.15	4.42
Total Long-Term Liabilities	4.63	6.33
Total Liabilities	8.07	25.03
Common Stock	0.49	0.36
Additional Paid-in Capital	281.99	272.26
Retained Earnings	-282.56	-274.07
Total Common Shareholders' Equity	-0.08	-1.45
Minority Interest	12.06	16.29
Shareholders' Equity	11.98	14.84
Total Liabilities & Equity	20.05	39.86
Total Debt	2.2	12.87
Net Cash (Debt)	10.76	2.43
Net Cash Growth	343.26%	-
Net Cash Per Share	1.37	0.43
Book Value	-0.08	-1.45
Book Value Per Share	-0.01	-0.25
Tangible Book Value	-0.08	-13.65
Tangible Book Value Per Share	-0.01	-2.40

Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q